{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:39:01Z","timestamp":1791567541046,"version":"4.3.4"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2020,6,25]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>The liver represents the major site of drug metabolism, i.e. the key organ in the processes of detoxification and elimination of drugs from the organism. It is therefore often affected by toxic metabolites and suffers sometimes fatal consequences. The spectrum of pathologies differs by the cell type primarily damaged and the group of the cholangiopathies includes those conditions affecting the bile duct epithelium or the cholangiocytes. They can range from transient cholestasis to vanishing bile duct syndrome and sclerosing cholangitis, both leading eventually to the development of biliary fibrosis and cirrhosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>In this review article, we focus on the etiology, predisposing factors, clinical manifestations, and histopathological characteristics of bile duct injury as a consequence of drug treatment and discuss separately the different bile duct pathologies.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389200221666200420100129","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T15:28:17Z","timestamp":1587396497000},"page":"256-259","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug-induced Bile Duct Injury - A Short Review"],"prefix":"10.2174","volume":"21","author":[{"given":"Inna","family":"Dobreva","sequence":"first","affiliation":[{"name":"Interventional Gastroenterology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2297-547X","authenticated-orcid":true,"given":"Petko","family":"Karagyozov","sequence":"additional","affiliation":[{"name":"Interventional Gastroenterology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1097\/01.mcg.0000155549.29643.ad","volume":"39","author":"Strazzabosco M.","year":"2005","unstructured":"Strazzabosco M.; Fabris L.; Spirli C.; Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005,39(4)(Suppl. 2),S90-S102","journal-title":"J Clin Gastroenterol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","volume":"1864","author":"Visentin M.","year":"2018","unstructured":"Visentin M.; Lenggenhager D.; Gai Z.; Kullak-Ublick G.A.; Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis 2018,1864(4 Pt B),1498-1506","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/17425255.2012.674511","volume":"8","author":"\u00d6sterreicher C.H.","year":"2012","unstructured":"\u00d6sterreicher C.H.; Trauner M.; Xenobiotic-induced liver injury and fibrosis. Expert Opin Drug Metab Toxicol 2012,8(5),571-580","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.14218\/JCTH.2018.00042","volume":"7","author":"Kolari\u0107 T.O.","year":"2019","unstructured":"Kolari\u0107 T.O.; Nin\u010devi\u0107 V.; Smoli\u0107 R.; Smoli\u0107 M.; Wu G.Y.; Mechanisms of hepatic cholestatic drug injury. J Clin Transl Hepatol 2019,7(1),86-92","journal-title":"J Clin Transl Hepatol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep4.1088","volume":"1","author":"Sundaram V.","year":"2017","unstructured":"Sundaram V.; Bjornsson E.; Drug-induced cholestasis. Hepatol Commun 2017,1,726-735","journal-title":"Hepatol Commun"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/14740338.6.6.673","volume":"6","author":"Hussaini S.H.","year":"2007","unstructured":"Hussaini S.H.; Farrington E.A.; Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007,6(6),673-684","journal-title":"Expert Opin Drug Saf"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1002\/jps.23584","volume":"102","author":"Yang K.","year":"2013","unstructured":"Yang K.; K\u00f6ck K.; Sedykh A.; Tropsha A.; Brouwer K.L.; An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci 2013,102(9),3037-3057","journal-title":"J Pharm Sci"},{"key":"ref=8","first-page":"106","volume":"27","author":"Hofmann A.F.","year":"1995","unstructured":"Hofmann A.F.; Bile acids as drugs: principles, mechanisms of action and formulations. Ital J Gastroenterol 1995,27(2),106-113","journal-title":"Ital J Gastroenterol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-2006-960172","volume":"27","author":"Trauner M.","year":"2007","unstructured":"Trauner M.; Fickert P.; Wagner M.; MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007,27(1),77-98","journal-title":"Semin Liver Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/hep.21359","volume":"44","author":"Pauli-Magnus C.","year":"2006","unstructured":"Pauli-Magnus C.; Meier P.J.; Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006,44(4),778-787","journal-title":"Hepatology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","volume":"17","author":"Lang C.","year":"2007","unstructured":"Lang C.; Meier Y.; Stieger B.; Beuers U.; Lang T.; Kerb R.; Kullak-Ublick G.A.; Meier P.J.; Pauli-Magnus C.; Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007,17(1),47-60","journal-title":"Pharmacogenet Genomics"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","volume":"339","author":"Trauner M.","year":"1998","unstructured":"Trauner M.; Meier P.J.; Boyer J.L.; Molecular pathogenesis of cholestasis. N Engl J Med 1998,339(17),1217-1227","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/archinte.156.12.1327","volume":"156","author":"Garc\u00eda Rodr\u00edguez L.A.","year":"1996","unstructured":"Garc\u00eda Rodr\u00edguez L.A.; Stricker B.H.; Zimmerman H.J.; Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996,156(12),1327-1332","journal-title":"Arch Intern Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0168-8278(97)82330-6","volume":"26","author":"Desmet V.J.","year":"1997","unstructured":"Desmet V.J.; Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997,26(Suppl. 1),31-35","journal-title":"J Hepatol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cphy.c120019","volume":"3","author":"Tabibian J.H.","year":"2013","unstructured":"Tabibian J.H.; Masyuk A.I.; Masyuk T.V.; O\u2019Hara S.P.; LaRusso N.F.; Physiology of cholangiocytes. Compr Physiol 2013,3(1),541-565","journal-title":"Compr Physiol"},{"key":"ref=16","first-page":"1232","volume":"15","author":"Geubel A.P.","year":"2000","unstructured":"Geubel A.P.; Sempoux C.L.; Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000,15(11),1232-1238","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2036.2010.04320.x","volume":"32","author":"Bj\u00f6rnsson E.","year":"2010","unstructured":"Bj\u00f6rnsson E.; Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010,32(1),3-13","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1053\/j.gastro.2010.04.001","volume":"138","author":"Chalasani N.","year":"2010","unstructured":"Chalasani N.; Bj\u00f6rnsson E.; Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010,138(7),2246-2259","journal-title":"Gastroenterology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0168-8278(92)90029-O","volume":"15","author":"Olsson R.","year":"1992","unstructured":"Olsson R.; Wiholm B-E.; Sand C.; Zettergren L.; Hultcrantz R.; Myrhed M.; Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992,15(1-2),154-161","journal-title":"J Hepatol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","volume":"58","author":"de Abajo F.J.","year":"2004","unstructured":"de Abajo F.J.; Montero D.; Madurga M.; Garc\u00eda Rodr\u00edguez L.A.; Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004,58(1),71-80","journal-title":"Br J Clin Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hep.22272","volume":"47","author":"Lammert C.","year":"2008","unstructured":"Lammert C.; Einarsson S.; Saha C.; Niklasson A.; Bjornsson E.; Chalasani N.; Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008,47(6),2003-2009","journal-title":"Hepatology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"Daly A.K.","year":"2009","unstructured":"Daly A.K.; Donaldson P.T.; Bhatnagar P.; Shen Y.; Pe\u2019er I.; Floratos A.; Daly M.J.; Goldstein D.B.; John S.; Nelson M.R.; Graham J.; Park B.K.; Dillon J.F.; Bernal W.; Cordell H.J.; Pirmohamed M.; Aithal G.P.; Day C.P.; HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet DILIGEN Study2009,41(7),816-819","journal-title":"Nat Genet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/hep.20215","volume":"39","author":"Andrade R.J.","year":"2004","unstructured":"Andrade R.J.; Lucena M.I.; Alonso A.; Garc\u00eda-Cortes M.; Garc\u00eda-Ruiz E.; Benitez R.; Fern\u00e1ndez M.C.; Pelaez G.; Romero M.; Corpas R.; Dur\u00e1n J.A.; Jim\u00e9nez M.; Rodrigo L.; Nogueras F.; Mart\u00edn-Vivaldi R.; Navarro J.M.; Salmer\u00f3n J.; de la Cuesta F.S.; Hidalgo R.; HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004,39(6),1603-1612","journal-title":"Hepatology"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/hep.28967","volume":"65","author":"Bonkovsky H.L.","year":"2016","unstructured":"Bonkovsky H.L.; Kleiner D.E.; Gu J.; Odin J.A.; Russo M.W.; Navarro V.M.; Fontana R.J.; Ghabril M.S.; Barnhart H.; Hoofnagle J.H.; Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology U.S.D.I.L.I.N Investigators, 2016,65(4),1267-1277","journal-title":"Hepatology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI113355","volume":"81","author":"Alpini G.","year":"1988","unstructured":"Alpini G.; Lenzi R.; Sarkozi L.; Tavoloni N.; Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 1988,81(2),569-578","journal-title":"J Clin Invest"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0950-3528(88)90010-3","volume":"2","author":"Larrey D.","year":"1988","unstructured":"Larrey D.; Erlinger S.; Drug-induced cholestasis. Baillieres Clin Gastroenterol 1988,2(2),423-452","journal-title":"Baillieres Clin Gastroenterol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hep.510240317","volume":"24","author":"Leon M.P.","year":"1996","unstructured":"Leon M.P.; Bassendine M.F.; Wilson J.L.; Ali S.; Thick M.; Kirby J.A.; Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology 1996,24(3),561-567","journal-title":"Hepatology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3748\/wjg.15.1677","volume":"15","author":"Perez M.J.","year":"2009","unstructured":"Perez M.J.; Briz O.; Bile-acid-induced cell injury and protection. World J Gastroenterol 2009,15(14),1677-1689","journal-title":"World J Gastroenterol"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.07.015","author":"Bhamidimarri K.R.","unstructured":"Bhamidimarri K.R.; Schiff E.; Drug-induced cholestasis Clin Liver Dis, 2013, 17(4), 519-531, vii","journal-title":"Drug-induced cholestasis Clin Liver Dis, 2013, 17(4), 519-531, vii"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s13181-010-0019-4","volume":"6","author":"Herrero-Herrero J-I.","year":"2010","unstructured":"Herrero-Herrero J-I.; Garc\u00eda-Aparicio J.; Corticosteroid therapy in a case of severe cholestasic hepatitis associated with amoxicillin-clavulanate. J Med Toxicol 2010,6(4),420-423","journal-title":"J Med Toxicol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.3747\/co.21.1592","volume":"21","author":"Ko Y.J.","year":"2014","unstructured":"Ko Y.J.; Karanicolas P.J.; Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era. Curr Oncol 2014,21(1),e116-e121","journal-title":"Curr Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1245\/s10434-011-2102-8","volume":"19","author":"Ito K.","year":"2012","unstructured":"Ito K.; Ito H.; Kemeny N.E.; Gonen M.; Allen P.J.; Paty P.B.; Fong Y.; Dematteo R.P.; Blumgart L.H.; Jarnagin W.R.; D\u2019Angelica M.I.; Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol 2012,19(5),1609-1617","journal-title":"Ann Surg Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/08941930490524363","volume":"17","author":"Sahin M.","year":"2004","unstructured":"Sahin M.; Eryilmaz R.; Bulbuloglu E.; The effect of scolicidal agents on liver and biliary tree (experimental study). J Invest Surg 2004,17(6),323-326","journal-title":"J Invest Surg"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.dld.2015.03.002","volume":"47","author":"Gudnason H.O.","year":"2015","unstructured":"Gudnason H.O.; Bj\u00f6rnsson H.K.; Gardarsdottir M.; Thorisson H.M.; Olafsson S.; Bergmann O.M.; Bj\u00f6rnsson E.S.; Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liver Dis 2015,47(6),502-507","journal-title":"Dig Liver Dis"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T20:39:26Z","timestamp":1666384766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181082\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221666200420100129","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}